CARDIAC ALLOGRAFT VASCULOPATHY
Clinical trials for CARDIAC ALLOGRAFT VASCULOPATHY explained in plain language.
Never miss a new study
Get alerted when new CARDIAC ALLOGRAFT VASCULOPATHY trials appear
Sign up with your email to follow new studies for CARDIAC ALLOGRAFT VASCULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new drug combo shield young hearts from transplant complications?
Disease control CompletedThis trial tests whether a combination of everolimus and low-dose tacrolimus is better than the standard tacrolimus plus mycophenolate mofetil at preventing serious long-term complications in children who have had a heart transplant. The study will follow 211 participants from 25…
Matched conditions: CARDIAC ALLOGRAFT VASCULOPATHY
Phase: PHASE3 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Heart transplant patients get new weapon against hidden artery damage
Disease control CompletedThis study tested the drug alirocumab in 114 heart transplant recipients to see if it safely reduces plaque buildup in the new heart's arteries. The drug targets a protein called PCSK9 to lower harmful cholesterol. Researchers measured changes in artery plaque using ultrasound at…
Matched conditions: CARDIAC ALLOGRAFT VASCULOPATHY
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC